TY - JOUR
T1 - General anesthetic actions on GABAA receptors in vivo are reduced in phospholipase C-related catalytically inactive protein knockout mice
AU - Hayashiuchi, Masaki
AU - Kitayama, Tomoya
AU - Morita, Katsuya
AU - Yamawaki, Yosuke
AU - Oue, Kana
AU - Yoshinaka, Taiga
AU - Asano, Satoshi
AU - Harada, Kae
AU - Kang, Youngnam
AU - Hirata, Masato
AU - Irifune, Masahiro
AU - Okada, Mitsugi
AU - Kanematsu, Takashi
N1 - Funding Information:
We thank the staff of the Natural Science Center for Basic Research and Development (NBARD) at Hiroshima University for assistance with mouse breeding. This work was supported in part by grants from the Japan Society for the Promotion of Science (JSPS; Kakenhi, Grant Numbers: JP26670809 and JP16K11503 to T. Kanematsu, JP15K11313 to M. I.).
Publisher Copyright:
© 2017, Japanese Society of Anesthesiologists.
PY - 2017/8/1
Y1 - 2017/8/1
N2 - Purpose: The aim of this study was to investigate the action of general anesthetics in phospholipase C-related catalytically inactive protein (PRIP)-knockout (KO) mice that alter GABAA receptor signaling. Methods: PRIP regulates the intracellular trafficking of β subunit-containing GABAA receptors in vitro. In this study, we examined the effects of intravenous anesthetics, propofol and etomidate that act via β subunit-containing GABAA receptors, in wild-type and Prip-KO mice. Mice were intraperitoneally injected with a drug, and a loss of righting reflex (LORR) assay and an electroencephalogram analysis were performed. Results: The cell surface expression of GABAA receptor β3 subunit detected by immunoblotting was decreased in Prip-knockout brain compared with that in wild-type brain without changing the expression of other GABAA receptor subunits. Propofol-treated Prip-KO mice exhibited significantly shorter duration of LORR and had lower total anesthetic score than wild-type mice in the LORR assay. The average duration of sleep time in an electroencephalogram analysis was shorter in propofol-treated Prip-KO mice than in wild-type mice. The hypnotic action of etomidate was also reduced in Prip-KO mice. However, ketamine, an NMDA receptor antagonist, had similar effects in the two genotypes. Conclusion: PRIP regulates the cell surface expression of the GABAA receptor β3 subunit and modulates general anesthetic action in vivo. Elucidation of the involved regulatory mechanisms of GABAA receptor-dependent signaling would inform the development of safer anesthetic therapies for clinical applications.
AB - Purpose: The aim of this study was to investigate the action of general anesthetics in phospholipase C-related catalytically inactive protein (PRIP)-knockout (KO) mice that alter GABAA receptor signaling. Methods: PRIP regulates the intracellular trafficking of β subunit-containing GABAA receptors in vitro. In this study, we examined the effects of intravenous anesthetics, propofol and etomidate that act via β subunit-containing GABAA receptors, in wild-type and Prip-KO mice. Mice were intraperitoneally injected with a drug, and a loss of righting reflex (LORR) assay and an electroencephalogram analysis were performed. Results: The cell surface expression of GABAA receptor β3 subunit detected by immunoblotting was decreased in Prip-knockout brain compared with that in wild-type brain without changing the expression of other GABAA receptor subunits. Propofol-treated Prip-KO mice exhibited significantly shorter duration of LORR and had lower total anesthetic score than wild-type mice in the LORR assay. The average duration of sleep time in an electroencephalogram analysis was shorter in propofol-treated Prip-KO mice than in wild-type mice. The hypnotic action of etomidate was also reduced in Prip-KO mice. However, ketamine, an NMDA receptor antagonist, had similar effects in the two genotypes. Conclusion: PRIP regulates the cell surface expression of the GABAA receptor β3 subunit and modulates general anesthetic action in vivo. Elucidation of the involved regulatory mechanisms of GABAA receptor-dependent signaling would inform the development of safer anesthetic therapies for clinical applications.
UR - http://www.scopus.com/inward/record.url?scp=85017093186&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85017093186&partnerID=8YFLogxK
U2 - 10.1007/s00540-017-2350-2
DO - 10.1007/s00540-017-2350-2
M3 - Article
C2 - 28389811
AN - SCOPUS:85017093186
SN - 0913-8668
VL - 31
SP - 531
EP - 538
JO - Journal of Anesthesia
JF - Journal of Anesthesia
IS - 4
ER -